샘플 요청 목록

 카트 문의
시장보고서
상품코드
1534042

세계의 천연두 치료 시장

Smallpox Treatment
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 250 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

천연두 치료 세계 시장 규모는 2030년까지 7,370만 달러에 달할 것으로 전망

2023년 6,550만 달러로 추정되는 천연두 치료 세계 시장은 2030년에는 7,370만 달러에 달할 것으로 예상되며, 분석 기간인 2023-2030년 동안 연평균 1.7% 성장할 것으로 예상됩니다. 이 보고서에서 분석한 부문 중 하나인 항바이러스제는 CAGR 1.6%를 기록하여 분석 기간 종료 시점에 3,250만 달러에 도달할 것으로 예상됩니다. 예방접종 부문의 성장률은 분석 기간 동안 CAGR 2.0%로 추정됩니다.

미국 시장은 1,780만 달러로 추정, 중국은 CAGR 3.0%로 성장할 것으로 예상

미국의 천연두 치료 시장은 2023년 1,780만 달러 규모에 달할 것으로 예상됩니다. 세계 2위의 경제 대국인 중국은 2023년부터 2030년까지 연평균 3.0%의 성장률을 보이며 2030년에는 1,350만 달러의 시장 규모에 도달할 것으로 예상됩니다. 다른 주목할 만한 지역 시장으로는 일본과 캐나다가 있으며, 분석 기간 동안 각각 0.8%와 1.5%의 CAGR을 기록할 것으로 예측됩니다. 유럽에서는 독일이 연평균 1.1%의 성장률을 보일 것으로 예상됩니다.

천연두 치료 시장 - 주요 동향 및 촉진요인 요약

천연두는 1980년 박멸이 선언된 심각한 전염병이지만, 결정적인 치료법이 없기 때문에 의료 관리는 주로 지지 요법에 초점을 맞추고 있습니다. 생물학 무기로 사용될 수 있다는 우려 때문에 치료 프로토콜은 바이러스 감염을 막기 위해 모든 딱지가 벗겨질 때까지 감염된 환자를 격리하는 것으로 되어 있지만, FDA가 2018년 테코빌리마트, 2021년 브린시도포비르와 같은 의약품을 승인함에 따라 FDA는 의약품 개발을 촉진하고 국민 혈액 공급의 안전을 보장함으로써 천연두 치료의 가용성을 보장하는 데 중요한 역할을 하고 있으며, 동물 실험에서 효능이 입증되고 긴급 사용 프로토콜이 승인됨에 따라 치료 옵션이 크게 발전하고 있습니다. ACAM2000, Jynneos, 그리고 임상시험 중인 Aventis Pasteur Smallpox Vaccine과 같은 백신은 전략적 국가 비축물량으로 매우 중요하며, 전염병이 유행할 때 배포할 수 있도록 준비돼 있습니다. 경구용과 정맥주사제 모두 사용 가능한 테코빌리마트와 브린시도포비르와 같은 치료제도 비상용 자원의 일부입니다.

수십 년 전 천연두가 근절되었음에도 불구하고 천연두 치료 및 예방 조치가 채택되고 있는 배경에는 몇 가지 요인이 있습니다. 첫 번째는 천연두가 생물무기로 사용될 수 있는 생물테러의 위협이 전 세계 각국 정부의 정책 및 의료 전략에 큰 영향을 미치고 있다는 점입니다. 이러한 잠재적 위협은 백신과 항바이러스제의 지속적인 연구와 비축을 보장하고 있습니다. 의학 연구의 기술 발전으로 보다 효과적이고 안전한 천연두 백신과 치료제가 개발되어 보급이 확대되고 있습니다. 또한, 세계 보건 안보 노력은 잠재적인 대유행에 대비하는 것의 중요성을 강조하고 진단 및 치료 옵션의 발전을 촉진하고 있습니다. 공중보건 정책도 중요한 역할을 하고 있으며, 백신과 항바이러스제의 전략적 비축을 유지하는 등 전염병 발생에 대응하기 위한 특정 프로토콜이 의무화되어 있습니다. 마지막으로, 감염병 대응을 위한 국제 협력과 자금 지원은 천연두 의료 대책의 준비와 가용성을 더욱 지원하고 향후 발생할 수 있는 대유행에 대한 세계 방패를 강화할 수 있습니다.

조사 대상 기업 예시(총 86건)

  • Bavarian Nordic AS
  • Chimerix, Inc.
  • Emergent BioSolutions Inc.
  • Emergex Vaccines
  • EpiVax, Inc.
  • Oncovir, Inc.
  • Pfizer, Inc.
  • Sanofi SA
  • SIGA Technologies Inc
  • Tonix Pharmaceuticals Holding Corp.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 성장 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

ksm 24.09.04

Global Smallpox Treatment Market to Reach US$73.7 Million by 2030

The global market for Smallpox Treatment estimated at US$65.5 Million in the year 2023, is expected to reach US$73.7 Million by 2030, growing at a CAGR of 1.7% over the analysis period 2023-2030. Antiviral Drugs, one of the segments analyzed in the report, is expected to record a 1.6% CAGR and reach US$32.5 Million by the end of the analysis period. Growth in the Vaccinations segment is estimated at 2.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$17.8 Million While China is Forecast to Grow at 3.0% CAGR

The Smallpox Treatment market in the U.S. is estimated at US$17.8 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$13.5 Million by the year 2030 trailing a CAGR of 3.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.8% and 1.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.1% CAGR.

Smallpox Treatment - Key Trends and Drivers

The medical management of smallpox, a severe infectious disease declared eradicated in 1980, largely focuses on supportive care as no definitive treatment exists. With concerns about its potential use as a bioweapon, the treatment protocol involves isolation of infected patients until all scabs have fallen off to prevent virus transmission. With the FDA's approval of drugs like tecovirimat in 2018 and brincidofovir in 2021, there has been significant advancement in the therapeutic options available, demonstrating effectiveness in animal studies and approved under protocols for emergency use. The FDA plays a critical role in ensuring the availability of medical countermeasures against smallpox through facilitating drug development and ensuring the safety of the nation's blood supply. Vaccines like ACAM2000, Jynneos, and the investigational Aventis Pasteur Smallpox Vaccine are crucial in the Strategic National Stockpile, ready for deployment in case of an outbreak. Treatment drugs such as tecovirimat, available in both oral and intravenous forms, and brincidofovir are part of the emergency resources.

Several factors drive the adoption of smallpox treatments and preventive measures despite the eradication of the disease decades ago. Primarily, the persistent threat of bioterrorism where smallpox could be used as a biological weapon significantly influences government policies and healthcare strategies worldwide. This potential threat ensures continued research into and stockpiling of vaccines and antiviral medications. Technological advances in medical research allow for more effective and safer smallpox vaccines and treatments, increasing their adoption. Furthermore, global health security initiatives emphasize the importance of preparedness for potential outbreaks, pushing for advancements in diagnostic and therapeutic options. Public health policies also play a crucial role; they mandate certain protocols for handling outbreaks, which include the maintenance of strategic reserves of vaccines and antivirals. Finally, international cooperation and funding for infectious disease control further support the readiness and availability of smallpox medical countermeasures, reinforcing a global shield against possible future outbreaks.

Select Competitors (Total 86 Featured) -

  • Bavarian Nordic AS
  • Chimerix, Inc.
  • Emergent BioSolutions Inc.
  • Emergex Vaccines
  • EpiVax, Inc.
  • Oncovir, Inc.
  • Pfizer, Inc.
  • Sanofi SA
  • SIGA Technologies Inc
  • Tonix Pharmaceuticals Holding Corp.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Smallpox Treatment - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Global Health Security Initiatives Drive Demand for Smallpox Treatments
    • Technological Advancements in Vaccine Storage and Stability
    • Emergence of Drug-Resistant Smallpox Strains Spurs Innovation
    • Enhancements in Vaccine Delivery Methods Propel Market Growth
    • Rise in Bioterrorism Threats Catalyzing Smallpox Preparedness
    • Collaborations between Governments and Pharmaceutical Companies
    • Advancements in Diagnostic Techniques Boosting Treatment Efficacy
    • Global Health Organizations' Focus on Eradication Programs
    • Funding Increases for Infectious Disease Research and Development
    • Integration of AI in Epidemiological Predictions and Vaccine Development
    • Regulatory Fast-Tracking of Critical Smallpox Medications
    • Ethical and Legal Challenges in Vaccine Deployment
    • Global Health Organizations Focus on Eradication Programs
    • Public Awareness and Education Campaigns Impact on Treatment Uptake
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Smallpox Treatment Market Analysis of Annual Sales in US$ for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Smallpox Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Smallpox Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Smallpox Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Antiviral Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Antiviral Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Antiviral Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Vaccinations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Vaccinations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Vaccinations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Supportive Care by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Supportive Care by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Supportive Care by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Hospitals & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Smallpox Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Smallpox Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antiviral Drugs, Vaccinations and Supportive Care for the Years 2014, 2024 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Smallpox Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Smallpox Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antiviral Drugs, Vaccinations and Supportive Care for the Years 2014, 2024 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Smallpox Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • JAPAN
    • Smallpox Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Smallpox Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antiviral Drugs, Vaccinations and Supportive Care for the Years 2014, 2024 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Smallpox Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • CHINA
    • Smallpox Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 40: China 16-Year Perspective for Smallpox Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antiviral Drugs, Vaccinations and Supportive Care for the Years 2014, 2024 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 43: China 16-Year Perspective for Smallpox Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • EUROPE
    • Smallpox Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Smallpox Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Smallpox Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Smallpox Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Smallpox Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antiviral Drugs, Vaccinations and Supportive Care for the Years 2014, 2024 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Smallpox Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • FRANCE
    • Smallpox Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 55: France 16-Year Perspective for Smallpox Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antiviral Drugs, Vaccinations and Supportive Care for the Years 2014, 2024 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 58: France 16-Year Perspective for Smallpox Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • GERMANY
    • Smallpox Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Smallpox Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antiviral Drugs, Vaccinations and Supportive Care for the Years 2014, 2024 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Smallpox Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Smallpox Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antiviral Drugs, Vaccinations and Supportive Care for the Years 2014, 2024 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Smallpox Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Smallpox Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Smallpox Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antiviral Drugs, Vaccinations and Supportive Care for the Years 2014, 2024 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Smallpox Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 79: Spain 16-Year Perspective for Smallpox Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antiviral Drugs, Vaccinations and Supportive Care for the Years 2014, 2024 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Smallpox Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 85: Russia 16-Year Perspective for Smallpox Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antiviral Drugs, Vaccinations and Supportive Care for the Years 2014, 2024 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Smallpox Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Smallpox Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antiviral Drugs, Vaccinations and Supportive Care for the Years 2014, 2024 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Smallpox Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Smallpox Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Smallpox Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Smallpox Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Smallpox Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Smallpox Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antiviral Drugs, Vaccinations and Supportive Care for the Years 2014, 2024 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Smallpox Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Smallpox Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 106: Australia 16-Year Perspective for Smallpox Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antiviral Drugs, Vaccinations and Supportive Care for the Years 2014, 2024 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Smallpox Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • INDIA
    • Smallpox Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 112: India 16-Year Perspective for Smallpox Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antiviral Drugs, Vaccinations and Supportive Care for the Years 2014, 2024 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 115: India 16-Year Perspective for Smallpox Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 118: South Korea 16-Year Perspective for Smallpox Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antiviral Drugs, Vaccinations and Supportive Care for the Years 2014, 2024 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Smallpox Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Smallpox Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antiviral Drugs, Vaccinations and Supportive Care for the Years 2014, 2024 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Smallpox Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Smallpox Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Smallpox Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Smallpox Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 130: Latin America 16-Year Perspective for Smallpox Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Smallpox Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antiviral Drugs, Vaccinations and Supportive Care for the Years 2014, 2024 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Smallpox Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 139: Argentina 16-Year Perspective for Smallpox Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antiviral Drugs, Vaccinations and Supportive Care for the Years 2014, 2024 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Smallpox Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 145: Brazil 16-Year Perspective for Smallpox Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antiviral Drugs, Vaccinations and Supportive Care for the Years 2014, 2024 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Smallpox Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 151: Mexico 16-Year Perspective for Smallpox Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antiviral Drugs, Vaccinations and Supportive Care for the Years 2014, 2024 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Smallpox Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 157: Rest of Latin America 16-Year Perspective for Smallpox Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antiviral Drugs, Vaccinations and Supportive Care for the Years 2014, 2024 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Smallpox Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Smallpox Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Smallpox Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Smallpox Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 163: Middle East 16-Year Perspective for Smallpox Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Smallpox Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antiviral Drugs, Vaccinations and Supportive Care for the Years 2014, 2024 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Smallpox Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 172: Iran 16-Year Perspective for Smallpox Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antiviral Drugs, Vaccinations and Supportive Care for the Years 2014, 2024 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Smallpox Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 178: Israel 16-Year Perspective for Smallpox Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antiviral Drugs, Vaccinations and Supportive Care for the Years 2014, 2024 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Smallpox Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 184: Saudi Arabia 16-Year Perspective for Smallpox Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antiviral Drugs, Vaccinations and Supportive Care for the Years 2014, 2024 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Smallpox Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 190: UAE 16-Year Perspective for Smallpox Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antiviral Drugs, Vaccinations and Supportive Care for the Years 2014, 2024 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Smallpox Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 196: Rest of Middle East 16-Year Perspective for Smallpox Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antiviral Drugs, Vaccinations and Supportive Care for the Years 2014, 2024 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Smallpox Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • AFRICA
    • Smallpox Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Smallpox Treatment by Treatment Type - Antiviral Drugs, Vaccinations and Supportive Care Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 202: Africa 16-Year Perspective for Smallpox Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antiviral Drugs, Vaccinations and Supportive Care for the Years 2014, 2024 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Smallpox Treatment by End-Use - Hospitals & Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Smallpox Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제